Lonza Upgrades 2026 Margin Outlook as H1 Performance Surges Across All Business Platforms
核心洞察
Lonza reported H1 2026 CER sales growth of 16.0% to CHF 3.4 billion, with CORE EBITDA reaching CHF 1.2 billion and margin expanding 4.4 percentage points to 34.8%.
The company upgraded its full-year 2026 CORE EBITDA margin outlook to 33–34%, up from a prior target of above 32%, while confirming 11–12% CER sales growth.
All three business platforms delivered double-digit CER sales growth, with Advanced Synthesis leading at 27.7% and Specialised Modalities returning to strong growth at 22.6%.
Lonza Group AG (搜索) delivered a robust first-half 2026 performance, reporting CHF 3.4 billion in sales with constant exchange rate (CER) sales growth of 16.0%, driven by sustained commercial demand across all technologies and geographies. The contract development and manufacturing organization (CDMO) posted CORE EBITDA of CHF 1.2 billion, a 27.4% increase versus H1 2025, with the CORE EBITDA margin expanding by 4.4 percentage points to 34.8%. Free cash flow improved to CHF 0.4 billion, up CHF 0.3 billion from the prior-year period, primarily reflecting higher earnings and lower capital expenditure.
Wolfgang Wienand, CEO of Lonza, stated: "As macroeconomic and geopolitical volatility continues, Lonza's strong H1 2026 performance once again demonstrates the resilience and attractiveness of our unique business model, underpinned by the Lonza Engine and its distinctive set of strengths."
Upgraded Full-Year Outlook
Based on the sustained business momentum, Lonza upgraded its full-year 2026 CORE EBITDA margin outlook to a range of 33–34%, an increase from the previous guidance of above 32%. The company confirmed its expectation for CER sales growth of 11–12%. Lonza noted that H2 growth and profitability will reflect planned phasing of business activities, particularly within Advanced Synthesis, and a higher prior-year base. Assuming mid-July 2026 spot rates prevail through the second half, the company anticipates a foreign exchange headwind of approximately -2% to -3% on sales for the full year, largely driven by the weakening of the US Dollar in 2025.
Platform Performance: Broad-Based Growth
All three business platforms contributed to the strong H1 results, each delivering double-digit CER sales growth:
Integrated Biologics reported CER sales growth of 10.0% versus H1 2025, supported by maturing growth projects and robust base business performance. The CORE EBITDA margin remained flat at 36.0%, with improvements in the growth business from project ramp-ups offset by a weaker portfolio mix in the base business. The Vacaville site showed H1-weighted sales phasing, with full-year 2026 sales expected to be flat versus 2025. Lonza expanded a strategic long-term collaboration agreement with a leading US biopharmaceutical company for manufacturing a broad portfolio of clinical and commercial biologics across all US commercial-scale mammalian sites.
Advanced Synthesis delivered exceptionally strong CER sales growth of 27.7% versus H1 2025, fueled by continued demand across both Small Molecules and Bioconjugates, good operational execution at increased asset utilization, and a favorable portfolio mix. The CORE EBITDA margin improved by 6.8 percentage points to 48.1%. While H2 sales are expected to be higher than H1 in absolute terms, growth versus the prior year will moderate due to a significantly higher prior-year base and favorable H1 phasing.
Specialised Modalities returned to strong CER sales growth of 22.6% versus H1 2025. Microbial experienced exceptional growth from a lower prior-year base, favorable phasing, and a successful customer-related plant adaptation. Bioscience sustained healthy growth, and Cell & Gene showed strengthened operational performance toward the end of H1 2026, expected to support growth in H2. The CORE EBITDA margin improved materially by 10.7 percentage points to 28.0%. The platform saw a sixth commercial therapy approved within its Cell & Gene Technology Platform.
Strategic ADC Capacity Expansion
Lonza announced the further expansion of its commercial-scale aseptic antibody-drug conjugate (ADC) drug product capacity in Stein, Switzerland, with the addition of another commercial-scale multi-purpose filling line for ADCs, expected to be operational in 2030. This investment is supported by a long-term collaboration agreement with a major pharmaceutical company for clinical and commercial ADC supply. The expansion complements the dedicated commercial-scale aseptic ADC facility and the large-scale multi-purpose aseptic drug product facility in Stein, both currently under construction. Additionally, Lonza has decided to expand the capabilities of the large-scale drug product facility to include high-value small molecule drug products for a small additional capital expenditure, with operations now expected to start in 2028.
One Lonza Strategy and Capital Allocation
The agreement to divest the Capsules & Health Ingredients (CHI) business represents a milestone in Lonza's transformation into a pure-play CDMO. Following the expected closing before year-end 2026, Lonza will return CHF 500 million of near-term surplus capital through an expedited share buyback program, with remaining proceeds strengthening financial flexibility for disciplined organic investments and M&A opportunities. Capital expenditure in H1 2026 totaled CHF 0.5 billion, representing 15.7% of sales. For the full year, Lonza expects CapEx intensity as a percentage of sales to be in the middle of the mid-to-high-teens range. Strategic growth projects are progressing across Mammalian, Drug Product, Bioconjugates, and Cell & Gene, and the large-scale mammalian asset in Visp commenced commercial operations in H1 2026 as planned.